G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $83 | $51 | $31 | $45 |
| % Growth | 60.8% | 63% | -30.5% | – |
| Cost of Goods Sold | $7 | $4 | $2 | $0 |
| Gross Profit | $75 | $48 | $29 | $45 |
| % Margin | 91.3% | 92.7% | 93.6% | 100% |
| R&D Expenses | $44 | $83 | $76 | $73 |
| G&A Expenses | $0 | $0 | $0 | $68 |
| SG&A Expenses | $71 | $100 | $96 | $68 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$1 |
| Operating Expenses | $115 | $184 | $172 | $142 |
| Operating Income | -$40 | -$136 | -$142 | -$96 |
| % Margin | -47.9% | -265.4% | -452.6% | -213% |
| Other Income/Exp. Net | -$5 | -$10 | -$5 | -$1 |
| Pre-Tax Income | -$45 | -$146 | -$147 | -$98 |
| Tax Expense | $3 | $2 | $1 | $1 |
| Net Income | -$48 | -$148 | -$148 | -$99 |
| % Margin | -58.1% | -287.6% | -471.3% | -219.2% |
| EPS | -0.93 | -3.38 | -3.54 | -2.62 |
| % Growth | 72.5% | 4.5% | -35.1% | – |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 |
| Weighted Avg Shares Out | 52 | 44 | 42 | 38 |
| Weighted Avg Shares Out Dil | 52 | 44 | 42 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $1 |
| Interest Expense | $10 | $10 | $5 | $2 |
| Depreciation & Amortization | $1 | $1 | $0 | $1 |
| EBITDA | -$34 | -$135 | -$142 | -$95 |
| % Margin | -41.6% | -263% | -452.6% | -210.9% |